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Abstract: Selenoprotein genetic variations and suboptimal selenium (Se) levels may contribute to the
risk of colorectal cancer (CRC) development. We examined the association between CRC risk and
genotype for single nucleotide polymorphisms (SNPs) in selenoprotein and Se metabolic pathway
genes. Illumina Goldengate assays were designed and resulted in the genotyping of 1040 variants
in 154 genes from 1420 cases and 1421 controls within the European Prospective Investigation into
Cancer and Nutrition (EPIC) study. Multivariable logistic regression revealed an association of
144 individual SNPs from 63 Se pathway genes with CRC risk. However, regarding the selenoprotein
genes, only TXNRD1 rs11111979 retained borderline statistical significance after adjustment for
correlated tests (PACT = 0.10; PACT significance threshold was P < 0.1). SNPs in Wingless/Integrated
(Wnt) and Transforming growth factor (TGF) beta-signaling genes (FRZB, SMAD3, SMAD7) from
pathways affected by Se intake were also associated with CRC risk after multiple testing adjustments.
Interactions with Se status (using existing serum Se and Selenoprotein P data) were tested at the
SNP, gene, and pathway levels. Pathway analyses using the modified Adaptive Rank Truncated
Product method suggested that genes and gene x Se status interactions in antioxidant, apoptosis, and
TGF-beta signaling pathways may be associated with CRC risk. This study suggests that SNPs in the
Se pathway alone or in combination with suboptimal Se status may contribute to CRC development.
Keywords: selenium; selenium status; selenoprotein gene variation; selenium pathway; colorectal
neoplasms; selenoprotein P; prospective cohort; colorectal cancer risk; genetic epidemiology; biomarkers
1. Introduction
In Europe, colorectal cancer (CRC) is the cancer type with both the second highest incidence and
mortality rate [1]. Substantial CRC risk may derive from dietary factors, genetic variants, and their
interactions [2,3].
Experimental and observational evidence suggests that suboptimal dietary intakes of the
micronutrient selenium (Se) contribute to greater risk for the development of cancers at several
anatomical sites, including the colorectum [4–6]. In humans, Se exerts its potential anti-carcinogenic
properties through incorporation into 25 selenoproteins by the amino acid selenocysteine [7,8].
Several selenoproteins protect cells from damaging oxidative radicals including the glutathione
peroxidases (notably GPX1 and GPX4), components of the thioredoxin reductase system (TXNRD1-3)
and selenoprotein P (SELENOP; please note the modified selenoprotein nomenclature [9]) which is
also critical for Se transport [8,10,11].
The major mechanism through which Se is thought to influence the risk of CRC development
is variation in gene expression and biosynthesis of protective selenoproteins [12,13]. In rodent
models, adequate Se intake and selenoprotein expression have been shown to prevent colon cancer
while selenoprotein dysregulation may increase colon cancer risk [14–16]. Data from nutritional
intervention trials and epidemiological studies suggest implications for Se intake regarding CRC
risk could potentially be more important in individuals with particular selenoprotein genotypes
and/or in populations with low Se status, such as in Western Europe where the present study was
conducted [4,5,17,18]. Risk modification by sex has also been observed for CRC risk associations with
selenoprotein genotypes [19,20] and Se status [5,17].
Genetic variations in approximately half of the 25-known human selenoprotein genes have
been associated with susceptibility to CRC and/or colorectal adenoma (CRA) risk in at least seven
populations from Asia, North America and Europe; in addition some of these variants have been
shown to impact survival outcomes (reviewed in [4,21]). Although some of these studies have been
performed in suboptimal Se intake areas, large studies have more generally been conducted in Se-replete
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environments in North America and these have reported evidence both for [22,23] and against [17] an
association of selenoprotein genes with CRC risk. However, only a limited number of single nucleotide
polymorphisms (SNPs) in selected selenoprotein genes have been analyzed, while in several of these
reports the Se status of the analyzed cohort was not assessed.
To our knowledge, it is unknown which selenoproteins are critical in maintaining colonic health
and no study has comprehensively evaluated variation in all selenoprotein genes for association with
CRC risk. Moreover, interactions of selenoprotein genetic variations according to robust Se status
biomarkers have not been explored. As both genetic factors and dietary Se intake can influence the
pattern of selenoprotein expression and biosynthesis, we hypothesized that variation in selenoprotein
genes, and in related signaling pathway genes influenced by Se intake (together comprising the ‘Se
pathway’), affect CRC development risk, while Se status may modify this risk.
In this study, we have examined for the first time the association of detailed Se pathway gene
variation with cancer risk in 1420 CRC cases and 1421 controls within the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort. We previously reported in a subset of this
nested cohort with 966 case-control pairs that a higher Se status (ascertained by serum levels of Se and
SELENOP) was associated with a lower CRC risk [5]. In these Western European subjects, the mean
Se and SELENOP circulating levels were 84.0 µg/L and 4.3 mg/L in cases and 85.6 µg/L and 4.4 mg/L
in controls, respectively. Thus, our present study was conducted in a generally suboptimal Se status
population, as these Se concentrations are insufficient for optimal GPX3 expression and SELENOP
saturation [5,6]. We now report the interaction between these genes and their corresponding pathways
with Se status biomarkers and CRC risk.
2. Materials and Methods
2.1. Study Population and Design
EPIC is a multicenter prospective cohort study designed to investigate the association between
diet, lifestyle, genetic and environmental factors and the incidence of cancers. The rationale and
methods of the EPIC design have been described previously [24,25]. Briefly, 521,448 men and
women mostly aged 25–70 years were enrolled between 1992–2000 in 23 sub-cohorts in 10 European
countries (Denmark, France, Germany, Greece, Italy, The Netherlands, Norway, Spain, Sweden, and
United Kingdom). The present analysis is based on participant data from all sub-cohorts except
for Norway. At recruitment, standardized dietary, lifestyle and socio-demographic questionnaires
including information on physical activity, education, smoking and medical history; anthropometric
data, and blood samples were collected from participants. Blood and DNA samples are stored at the
International Agency for Research on Cancer (IARC, Lyon, France) at −196 ◦C under liquid nitrogen for
all countries except Denmark (−150 ◦C, nitrogen vapor) and Sweden (−80 ◦C freezers). Sample storage
standardization including DNA extraction and quantification protocols were previously described
in [26].
All study participants provided written informed consent. Ethical approval for the EPIC study
was obtained from the review boards of the IARC (IARC Ethics Committee) and local participating
centers. Study design methods were performed in accordance with the STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology) guidelines (https://www.strobe-statement.org/
index.php?id=strobe-home).
2.2. Follow-Up for Cancer Incidence
Cancer incidence was determined through record linkage with population-based cancer registries
(Denmark, Italy, Netherlands, Spain, Sweden, United Kingdom) or via a combination of methods,
including the use of health insurance records, cancer and pathology registries, and active contact of
study subjects or next-of-kin (France, Germany, Greece). Complete follow-up censoring dates for this
study varied among centers, ranging between June 2002 and June 2003.
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2.3. Selection of Cases and Controls and Study Design
Case subjects were men and women who developed first incident CRC after recruitment and before
the latest follow-up date. Cancer incidence data were coded using the 10th Revision of the International
Classification of Diseases (ICD-10) and the second revision of the International Classification of Disease
for Oncology (ICDO-2). Colon cancers were defined as tumors in the cecum, appendix, ascending
colon, hepatic flexure, transverse colon, splenic flexure, descending and sigmoid colon (C18.0-C18.7),
and overlapping or unspecified origin tumors (C18.8 and C18.9). Rectal cancers were defined as tumors
occurring at the recto-sigmoid junction (C19) or rectum (C20). Anal canal cancers (C21) were excluded.
Colorectal cancer is the combination of the colon and rectal cancer cases.
All subjects with prior cancer diagnosis at any site (except non-melanoma skin cancer) were
excluded. Cases were matched 1:1 by study center of enrollment, sex, age at blood collection, time of
blood collection and fasting status, and menopausal status among women. Premenopausal women
were matched on phase of menstrual cycle and postmenopausal women were matched on current
hormonal therapy (HT) use. The matching was done as part of a previously published study on
Se status [5], except for cases from Denmark for which new control subjects were identified due
to problems with accessing the biobank. Furthermore, additional newly identified cases with their
matching controls were also included for the genotyping from all participating countries but did not
have biomarkers of Se status. Sweden was the only country of the nine participating in the genetic
analysis for which we had no Se status data. Hence, there were 1478 cases and 1478 controls available
for genotyping but the Se status information was only available for 966 of the cases and for 966 of
the controls.
2.4. Gene Selection and Rationale
To examine selenoprotein gene and wider Se pathway gene variations in relation to CRC risk,
we selected 1264 functional and haplotype tagging SNPs (tagSNPs) to comprehensively analyze
common SNP variation in 164 Se pathway genes, which we assigned into eight functional pathways
(listed in Supplementary Table S1). These included 42 genes in the primary selenoprotein pathway
1 (25 selenoprotein genes and 17 genes involved in Se transport and metabolism), and 122 genes
in pathways 2–8 from (i) pathways affected by Se intake (Wnt, mTOR, Nrf2 and NF-κB signaling,
endoplasmic reticulum and oxidative stress responses), and (ii) associated pathways of inflammatory
response, apoptosis, DNA repair, Transforming growth factor (TGF) beta-signaling, and cell-cycle
control [12] as detailed in Méplan and Hesketh, 2012 [13]. Variants in several genes from these affiliated
pathways have been associated with CRC risk including regions of the Wingless/Integrated (Wnt)
signaling gene C-MYC in CRC genome-wide association studies (GWAS) [27]. Our SNP analysis
set was substantially enlarged from and included the 384 Se pathway SNPs (in 72 Se related genes)
Se ‘SNP-Chip’ devised for a similar study of gene-Se interaction in a prostate cancer study within
EPIC [28].
2.5. Tagging Single Nucleotide Polymorphism (tagSNP) Selection Protocol
A list of SNPs in all gene regions was compiled using the data from HapMap (release 27, based on
dbSNP version b126 and NCBI genome build 36). TagSNPs were selected by use of the Tagger algorithm
as implemented in the Haploview 3.2 software (Broad Institute, Cambridge, MA, USA). Parameters
used for SNP selection were a Minor Allele Frequency (MAF) ≥5% in Caucasians and pairwise tagging
(r2 ≥ 0.8). To include SNPs in promoter and potential regulatory regions, +/− 2 to 5 kilo base-pairs
beyond the 5′ and 3′ ends were included. Additionally, known functional variants in our selected
genes were added to the tagSNP list, e.g., for the selenoproteins these included rs7579, rs297299,
and rs3877899 in SELENOP [4]. Selected SNPs were then assessed for suitability for the Illumina
GoldenGateTM (Saffron Walden, Essex, UK) genotyping platform using Illumina’s custom assay building
platform (https://www.illumina.com/Documents/products/technotes/technote_goldengate_design.pdf).
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Fifty-five SNPs which failed assay development criteria were replaced by proxy SNPs, i.e., those within
the same genic region in high LD (r2 > 0.8) to the original SNP. Proxy SNP replacements for functional
selenoprotein SNPs which failed assay design included rs1800668 for GPX1-rs1050450, and rs5845 plus
rs540049 for SELENOF-rs5859. However, there were no adequate proxies for SELENOS-rs34713741 or
GPX4-rs713041.
2.6. Genotyping
A total of 1264 SNPs from 164 Se pathway genes were genotyped by Illumina GoldengateTM in
DNA samples available for 1478 case-control pairs matched within EPIC. Genotyping was performed
simultaneously for cases and controls, blinded to case-control status (but with matched pairs analyzed
in the same batch). A total of 62 replicate samples were genotyped to test for internal quality control,
approximately 2 per genotyping plate, with the lowest reproducibility frequency for each of the
replicates of 0.98. Samples with unclear or failed genotype calls were excluded from the analysis,
leaving 1420 cases and 1421 controls for subsequent analyses.
From the 1264 initially selected, 96 SNPs failed genotyping, 27 failed Hardy–Weinberg Equilibrium
(HWE), and 101 had less than 80% successfully genotyped samples. Thus, 1040 SNPs in 154 Genes
(24 selenoprotein genes analyzed of 25, and 130 other Se pathways genes) with at least 80% genotypes
across all genotyped samples were included in the final dataset (with a final genotyping call rate of
0.97, excluding zero call rate and those removed). Supplementary Table S2 provides the full gene and
SNP list successfully analyzed in the current study.
2.7. Selenium Status Assays
Measurements of serum Se and SELENOP were previously done for a subset (966 cases and
966 controls) of the current analyzed cohort. The methods used were described in Hughes et al., 2015
and Hybsier et al., 2017 [5,29]. Briefly, total Se levels were measured in 4 uL of each serum sample
using a bench-top total reflection X-ray fluorescence (TXRF) spectrometer (PicofoxTM S2, Bruker Nano
GmbH, Berlin, Germany). SELENOP protein concentrations were ascertained from 20 µL of each serum
sample by a colorimetric enzyme-linked immunoassay (Selenotest™, ICI GmbH, Berlin, Germany).
For quality-control, the sample type (case or control) was blinded and two serum samples of known Se
and SELENOP concentrations for intra-assay variability were included in each analysis plate. The
samples were measured in duplicate and the mean concentration values, standard deviation (SD),
and coefficient of variation (CV) were calculated. Duplicate samples with variances in concentration
over 10% were re-measured. The evaluation was performed using GraphPad Prism 6.01 (GraphPad
Software, La Jolla, CA, USA) using a four-parameter logistic function. The CV was 7.3% and 7.2% for
controls 1 (SELENOP: 1.5 mg/L) and 2 (SELENOP: 8.6 mg/L), respectively.
2.8. Statistical Analysis
Both unconditional and conditional logistic regression analysis were carried out to assess the
association of individual SNPs with CRC risk, adjusting for age (as a continuous variable), sex, and
study center and provided similar results. We present the data for the unconditional logistic regression.
Four standard genetic analysis models were tested for disease penetrance: multiplicative, additive,
common recessive, and common dominant models [30]. Sub-group analyses by sex and anatomical
sub-site of the colorectum (colon and rectum) were conducted. The associations between Se and
SELENOP concentrations and genetic variants (coded as 0, 1, 2 corresponding to the number of minor
alleles) were assessed among controls using linear regression models adjusted for age, sex, and center.
Further adjustment by body mass index (BMI), smoking status, and physical activity did not change
the results substantially.
Multiple testing corrections were performed by the Benjamini–Hochberg (BH) procedure [31].
P-values were also adjusted for correlated tests (PACT) to take account of the correlated nature of the
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SNP data in biologically relevant and related pathways [32]. BH was performed for all SNPs, followed
by PACT for the genes that had SNPs with P < 0.01.
We further employed exploratory gene- and pathway-based testing based on overall SNP
variation to help identify possible important Se related biological pathways and genes with multiple
risk variants that may be discounted in multiple testing corrections for the large number of SNPs
with small effect sizes in a SNP by SNP approach. Genes were classified a priori into a primary
best-known functional pathway based on the literature (listed in Supplementary Table S1). Gene-
and pathway-based P-values were computed using the PIGE (Self-Contained Gene Set Analysis for
Gene- and Pathway-Environment Interaction Analysis) R package which implements the modified
Adaptive Rank Truncated Product (ARTP) test using a permutation algorithm [33] to accommodate
gene-environment interactions (https://cran.rproject.org/web/packages/PIGE/index.html). Prior to this
analysis, SNPs in high linkage disequilibrium (LD) were removed using AdaJoint [34] and the online
tool SNPsnap (https://data.broadinstitute.org/mpg/snpsnap/about.html) so that all SNP pairs had LD
r2 < 0.8. Gene x Se status interactions were also examined using the PIGE R package. Although these
methods do not identify individual susceptibility loci, they may help to identify a pathway that could
modify the association between Se status and CRC risk. An advantage is that they do not require a
priori knowledge of directionality for the variants.
All statistical tests were two-sided, and P-values < 0.05 were considered statistically significant
(except P < 0.1 for PACT). Analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC,
USA) and R (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/)
statistical packages.
3. Results
3.1. Baseline Characteristics of Participants
The baseline characteristics of participants are presented in Table 1. Colon and rectal cancer cases
were diagnosed, on average, 4.1 and 4.2 years after blood collection, respectively. CRC cases were
overall less likely to be physically active compared to controls. There were no data on Se supplement
use for our study participants.
Table 1. Selected baseline characteristics of incident colon and rectal cancer cases and controls, the
European Prospective Investigation into Cancer and Nutrition (EPIC) study, 1992–2003.
Characteristic Colon Cancer Cases Rectal Cancer Cases Controls
N 900 520 1419
Women, N (%) 475 (52.8) 230 (44.2) 701 (49.4)
Mean age at blood collection, (SD) yrs 58.8 (7.5) 58.0 (6.9) 58.6 (7.4)
Mean years of follow-up (SD) yrs 4.1 (2.3) 4.2 (2.2)
Smoking status, N (%) *
Never 385 (42.8) 195 (37.5) 594 (41.9)
Former 299 (33.2) 177 (34) 460 (32.4)
Smoker 204 (22.7) 142 (27.3) 349 (24.6)
Physical activity, N (%) *
Inactive 129 (14.3) 73 (14) 183 (12.9)
Moderately inactive 257 (28.6) 145 (27.9) 367 (25.9)
Moderately active 374 (41.6) 209 (40.2) 612 (43.1)
Active 75 (8.3) 55 (10.6) 148 (10.4)
BMI, kg/m2, (SD) 26.9 (4.36) 26.6 (3.92) 26.3 (3.84)
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Table 1. Cont.
Characteristic Colon Cancer Cases Rectal Cancer Cases Controls
Country, N (%)
Sweden 55 (6.1) 33 (6.3) 86 (6.1)
Denmark 174 (19.3) 164 (31.5) 340 (24)
The Netherlands 99 (11) 54 (10.4) 158 (11.1)
United Kingdom 166 (18.4) 74 (14.2) 250 (17.6)
Germany 110 (12.2) 69 (13.3) 169 (11.9)
France 22 (2.4) 6 (1.2) 29 (2)
Italy 144 (16) 58 (11.2) 198 (14)
Spain 101 (11.2) 45 (8.7) 141 (9.9)
Greece 29 (3.2) 17 (3.3) 48 (3.4)
* Percentages do not add up to 100% due to missing values. Abbreviations: BMI, body mass index; N, sample size;
SD, standard deviation; yrs, years.
3.2. Se Pathway Genetic Variation and Colorectal Cancer (CRC) Risk Association
The 1040 tagging SNPs successfully analyzed from 154 genes and in HWE are shown in
Supplementary Table S2 (which also provides all the genetic analysis results for CRC, plus stratified
analyses for colon and rectal sub-site and by sex). These include 325 SNPs from 41 selenoprotein
and Se transport/selenoprotein biosynthesis genes (designated as the primary Se pathway 1), and
715 variants from the other 113 wider Se metabolic pathway genes (pathways 2–8). A summary of
the genetic associations before and after multiple testing corrections is provided in Supplementary
Figure S1. Prior to adjustment for multiple comparisons, there were 144 SNPs in 63 genes nominally
associated with CRC risk (P < 0.05 in at least one of the disease penetrance models tested; listed in
Supplementary Table S3). There were 28 unique SNPs in LD with other associated SNPs and these are
listed and highlighted in Supplementary Table S3 (tab ‘LD CEU’). Among the 40 SNPs significantly
associated with CRC risk from pathway 1, approximately half (21) were in 12 selenoprotein genes
(i.e., 50% of the 24 selenoprotein genes successfully genotyped out of 25) and have the potential to
affect the function or expression of individual selenoproteins, although this remains to be investigated.
These 12 selenoprotein genes include those previously found associated with CRC risk (GPX1, GPX4,
SELENOF, TXNRD1, TXNRD2, TXNRD3; for reviews, see [4,21]) and several with limited prior or
no previous evidence of association with CRC risk (DI01, GPX6, SELENOM, SELENON, SELENOT,
SELENOV). The other 19 SNPs associated with CRC in pathway 1 are in 8 of the 17 (47%) other Se
transport /selenoprotein biosynthesis genes. Therefore, they have the potential to affect the synthesis
of most selenoproteins (which also needs to be examined). Notably, 31% of the genes harboring
SNPs associated with CRC risk (20 of 63) were related to selenoprotein biosynthesis and function
implicated in protection from cancer development [4,21] with pathway 1 and 2 proteins involved
in (1) Se homeostasis (SELENOP, SEPHS1, SEPSEC, EFSEC, SCLY), (2) antioxidant enzymes (GPXs,
TXNRDs, SELENON), and (3) endoplasmic reticulum (ER) function or stress (SELENOF, SELENOM,
SELENOT, and again SELENON). Additionally, several of these genes (e.g., GPX1, GPX5, LRP2,
SEPHS1, SELENOM, SELENON, TXNRD1, and TXNRD2) had multiple SNPs and/or SNPs with raw
P-values < 0.01 associated with CRC risk further supporting a role of selenoproteins, selenoprotein
metabolism, ER stress, and oxidative stress in CRC development. Table 2 lists the SNPs in the primary
Se pathway 1 with raw P-values < 0.01 associated with CRC risk.
In pathways 3–8, considering genes with multiple SNPs associated with CRC risk or SNPs with raw
P-values < 0.01 for at least one genetic model, there were several notable and some novel associations
with CRC risk for genes in pathways 3 (C-MYC, FRZB), 4 (APAF1, BAX, FOXO3), 5 (IL12B, RPS6KA2,
TRL4), 6 (MSH2, MSH3) and 7 (BMP2, BMPR2, SMAD3, SMAD7, TFGB1).
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Table 2. Single nucleotide polymorphisms (SNPs) associated with colorectal cancer (CRC) risk in
primary selenium pathway 1 (selenium and selenoprotein transport, biosynthesis and metabolism)
with raw P-values < 0.01 in at least one genetic model prior to multiple testing adjustment, the EPIC
study, 1992–2003.
Gene/SNP/Genotype CRC Control OR (95% CI) P PBH +
GPX1/rs17080528
GG 700 620 1.00 (ref) 0.010 0.703
GA 580 636 0.81 (0.69,0.95)
AA 131 154 0.75 (0.58,0.97)
Additive * 1411 1410 0.84 (0.75,0.95) 0.003 0.554
Dominant (GA + AA vs. GG) 1411 1410 0.80 (0.69,0.92) 0.003 0.534
Recessive (AA vs. GG + GA) 1411 1410 0.83 (0.65,1.06) 0.137 0.854
SELENOM/rs11705137
AA 367 346 1.00 (ref) 0.024 0.753
AG 631 648 0.91 (0.75,1.09)
GG 288 359 0.74 (0.60,0.92)
Additive * 1286 1353 0.86 (0.78,0.96) 0.008 0.684
Dominant (AG + GG vs. AA) 1286 1353 0.85 (0.71,1.01) 0.064 0.815
Recessive (GG vs. AA + AG) 1286 1353 0.79 (0.66,0.95) 0.012 0.710
SELENON/rs4659382
GG 783 713 1.00 (ref) 0.019 0.747
GC 509 573 0.80 (0.69,0.94)
CC 96 107 0.82 (0.61,1.10)
Additive * 1388 1393 0.86 (0.76,0.97) 0.011 0.710
Dominant (GC + CC vs. GG) 1388 1393 0.81 (0.69,0.94) 0.005 0.625
Recessive (CC vs. GG + GC) 1388 1393 0.90 (0.67,1.20) 0.455 0.954
SEPHS1/rs2275129
GG 361 423 1.00 (ref) 0.032 0.780
GC 726 690 1.23 (1.03,1.47)
CC 321 295 1.28 (1.04,1.58)
Additive * 1408 1408 1.14 (1.02,1.26) 0.017 0.747
Dominant (GC + CC vs. GG) 1408 1408 1.25 (1.05,1.47) 0.010 0.697
Recessive (CC vs. GG + GC) 1408 1408 1.12 (0.94,1.34) 0.217 0.885
TXNRD1/rs11111979 ˆ
GG 395 429 1.00 (ref) 0.015 0.745
GC 627 680 1.00 (0.84,1.20)
CC 279 230 1.34 (1.07,1.67)
Additive * 1301 1339 1.14 (1.02,1.27) 0.022 0.749
Dominant (GC + CC vs. GG) 1301 1339 1.09 (0.92,1.28) 0.315 0.932
Recessive (CC vs. GG + GC) 1301 1339 1.33 (1.10,1.62) 0.004 0.566
+ = After Benjamini–Hochberg (BH) multiple testing correction; * = Additive models impose a structure in
which each additional copy of the variant allele increases the response (log odds ratio) by the same amount; ˆ =
TXNRD1 rs11111979 was borderline significant after adjustment for correlated tests (PACT = 0.10). EPIC = European
Prospective Investigation into Cancer and Nutrition.
None of the SNPs in the primary Se pathway 1 remained significant after multiple testing
corrections by the BH procedure. Overall, only 6 SNPs harbored by more distantly related genes
in cell-signaling pathways retained significance (FRZB, SMAD3, and SMAD7; see Table 3). Genes
harboring SNPs with raw P-values < 0.01 with CRC risk for at least one genetic model (21 genes/34
SNPs) were further considered for gene-wide variance significance by the PACT method. For pathway
1, the TXNRD1 selenoprotein variant rs11111979, an intron 3′–5′UTR SNP previously associated with
healthy aging [35], remained borderline significant for an association with CRC risk (PACT = 0.100;
PACT significance threshold was P < 0.1) in the recessive genetic model. Including FRZB, SMAD3 and
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SMAD7, the other wider pathway genes retaining significance were C-MYC (PACT = 0.032), BMP2
(PACT = 0.012) and BAX (PACT = 0.035).
Table 3. Single Nucleotide Polymorphisms (SNPs) statistically significantly associated with colorectal
cancer (CRC) risk after Benjamini–Hochberg (BH) multiple testing correction, the EPIC study, 1992–2003.
Gene/SNP/Genotype CRC Control OR (95% CI) P PBH
FRZB/rs17265803 ˆ
AA 844 976 1.00 (ref) 3.04E-06 0.003
AG 315 240 1.56 (1.28,1.89)
Additive * 1163 1232 1.35 (1.13,1.62) 0.001 0.372
Dominant (AG + GG vs. AA) 1163 1232 1.48 (1.22,1.79) 6.77E-05 0.034
Recessive (GG vs. AA + AG) 1163 1232 0.26 (0.09,0.80) 0.018 0.747
SMAD3/rs7180244 ˆ
GG 994 1183 1.00 (ref) 2.22E-16 1.12E-12
GC 372 198 2.33 (1.92,2.83)
Additive * 1372 1388 2.16 (1.79,2.60) 1.11E-15 3.74E-12
Dominant (GC + CC vs. GG) 1372 1388 2.28 (1.88,2.77) 1.11E-16 1.12E-12
Recessive (CC vs. GG + GC) 1372 1388 0.87 (0.29,2.61) 0.804 0.997
SMAD7/rs11874392
AA 478 400 1.00 (ref) 1.39E-07 2.82E-04
AT 704 671 0.88 (0.74,1.04)
TT 222 337 0.55 (0.44,0.68)
Additive * 1404 1408 0.75 (0.68,0.84) 1.99E-07 3.36E-04
Dominant (AT + TT vs. AA) 1404 1408 0.77 (0.65,0.90) 0.001 0.372
Recessive (TT vs. AA + AT) 1404 1408 0.59 (0.49,0.72) 6.26E-08 1.58E-04
SMAD7/rs12953717
GG 366 470 1.00 (ref) 3.47E-05 0.019
GA 671 643 1.36 (1.14,1.62)
AA 335 273 1.60 (1.29,1.98)
Additive * 1372 1386 1.27 (1.14,1.41) 9.07E-06 0.006
Dominant (GA + AA vs. GG) 1372 1386 1.43 (1.21,1.68) 2.38E-05 0.014
Recessive (AA vs. GG + GA) 1372 1386 1.32 (1.10,1.59) 0.003 0.534
SMAD7/rs4939827
AA 433 378 1.00 (ref) 6.46E-06 0.005
AG 664 634 0.92 (0.77,1.09)
GG 248 357 0.60 (0.49,0.75)
Additive * 1345 1369 0.79 (0.71,0.87) 9.46E-06 0.006
Dominant (AG + GG vs. AA) 1345 1369 0.80 (0.68,0.95) 0.009 0.697
Recessive (GG vs. AA + AG) 1345 1369 0.64 (0.53,0.77) 1.66E-06 0.002
SMAD7/rs6507874
AA 467 389 1.00 (ref) 1.93E-06 0.002
AG 705 677 0.87 (0.73,1.03)
GG 234 336 0.57 (0.46,0.71)
Additive * 1406 1402 0.77 (0.69,0.86) 1.26E-06 0.002
Dominant (AG + GG vs. AA) 1406 1402 0.77 (0.65,0.90) 0.001 0.420
Recessive (GG vs. AA + AG) 1406 1402 0.63 (0.52,0.76) 1.16E-06 0.002
ˆ = Results for the rare homozygous genotypes are omitted for these SNPs due to the small sample numbers
with these genotypes; * = Additive models impose a structure in which each additional copy of the variant allele
increases the response (log odds ratio) by the same amount. EPIC = European Prospective Investigation into Cancer
and Nutrition.
Supplementary Table S3 also catalogs the SNPs with raw significant P-values and the BH
corrections stratified by cancer sub-site (comprising 138 SNPs in 65 genes for colon in tab ‘colon cancer’
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and 123 SNPs in 54 genes for rectum listed in tab ‘rectal cancer’). Additionally, the tab ‘All’ lists all
the SNPs showing an association for CRC, colon only, rectal only, plus the analyses stratified by sex.
Generally, there was predominate overlap in the genes associated with CRC and sub-site risks. Genes
containing variants uniquely associated only with sub-site risk plus raw P-values < 0.01 comprised
rs12124257 in PTGS2 for colon cancer and 4 SNPs in IL10 for rectal cancer.
3.3. Associations Between Se Pathway Genetic Variation and Se Status
Among controls, 99 different SNPs in 55 genes were nominally associated with Se status (raw
P-values < 0.05). From these 99 variants, 87 SNPs from 45 genes were associated with either Se or
SELENOP levels (55 SNPs in 33 genes and 56 SNPs in 37 genes, respectively) while the other 12
variants from 10 genes were associated with both Se status measures, including 2 each in HIF1A and
SMAC. Eight pathway 1 genes harbored 14 SNPs significant for Se level changes (including 7 SNPs in
5 selenoprotein genes) while 9 pathway 1 genes carried 15 variants significant for SELENOP status
association (11 SNPs in 6 selenoprotein genes). However, none of the associations retained significance
after BH multiple testing adjustments. These SNP IDs together with the beta coefficients for change in
Se (µg/L) or SELENOP (mg/L) are listed according to gene pathway in Supplementary Table S4.
3.4. Pathway Analysis
An exploratory analysis of CRC risk with gene variation and gene x Se status interaction within
eight predefined pathways was performed using the PIGE package. A summary of the main PIGE
results per pathway is presented in Table 4, while Supplementary Table S5 provides all the P-values for
each gene per pathway designation. Considering nominal significance for association with disease risk
by pathway of P < 0.05, then these analyses suggest that TGF-beta signaling (P < 0.001) is the sole
pathway highly associated with CRC risk independent of Se status interaction. Antioxidant/redox
pathway genetic variation combined with Se status interactions was associated with a significant effect
on CRC risk (P = 0.011 and 0.010 for Se and SELENOP interactions, respectively), possibly driven by
SNPs in HIF1A, KEAP1, GPX7, CAT, and SOD2 (when considering the P-values for each individual
gene regarding gene only variation and gene x Se status interaction; see Supplementary Table S5). In
contrast, the risk association with gene variation in the apoptosis pathway seems to depend more on
interaction with Se levels (P = 0.003) but not with SELENOP concentrations (P = 0.105). For gene only
analyses there were several genes across the pathways associated with CRC risk including the pathway
1 genes GPX1, SELENOM, SELENON, and SEPHS1, from which only SELENON was significant for
both the gene only and gene x Se interaction PIGE analyses (Supplementary Table S5). In agreement
with previous large gene association and GWAS studies, overall genetic variation in the SMAD3,
SMAD7, BMP2, and BMPR2 genes was associated with CRC risk [36–38]. Excluding individuals with
no measurements of Se or SELENOP concentrations did not substantially change the main gene only
PIGE results (both sets of results are provided in Supplementary Table S5).
Table 4. P-values for genetic pathways and pathway-selenium (Se) status interactions and colorectal
cancer risk, the EPIC study, 1992–2003.
Pathway PPathway Only PPathway Only (non-Missing Se Status)*** PPathway x Se Interaction PPathway x SELENOP Interaction
Se and Selenoproteins * 0.217 0.098 0.615 0.726
Antioxidant and Redox 0.173 0.072 0.011 0.010
Cell signaling ** 0.307 0.489 0.223 0.872
Apoptosis 0.361 0.097 0.003 0.105
Inflammation 0.822 0.262 0.199 0.607
DNA repair 0.739 0.432 0.175 0.088
TGFβ signaling <0.001 0.001 0.061 0.764
Cell cycle control 0.398 0.475 0.097 0.449
* Se and selenoprotein transport, biosynthesis & metabolism. ** Includes Wnt, mTOR, NfkB, and Nrf2 signaling.
*** Includes only participants with non-missing blood Se or SELENOP concentrations. EPIC = European Prospective
Investigation into Cancer and Nutrition.
Nutrients 2019, 11, 935 12 of 19
4. Discussion
The results of this prospective nested case-control study represent the largest reported analysis of
both the association of Se pathway SNP variation and the interaction with Se status biomarkers (serum
Se levels and SELENOP protein concentrations) with CRC risk. The analysis of 1,040 tagSNPs in 154 Se
pathway genes in DNA samples from 1,420 CRC cases and 1,421 controls within EPIC indicated that
144 of these SNPs in 63 genes were nominally associated with CRC risk. However, for pathway 1 only
the TXNRD1 selenoprotein gene rs11111979 SNP retained borderline significance after correction for
multiple testing. For pathways 2–8, variants in BAX, BMP2, C-MYC, FRZB, SMAD3, and SMAD7
passed significance thresholds following these adjustments.
Selenoprotein genes nominally associated with CRC risk included several with limited or no
prior evidence (DIO1, GPX6, SELENOM, SELENON, SELENOT, SELENOV) and those reported in
several studies (GPX1, GPX4, SELENOF, TXNRD1, TXNRD2, TXNRD3) for an association with CRC (or
specifically colon or rectal cancer) risk. This latter group of genes has been more extensively examined
due to their putative roles related to cancer prevention in colonic tissue (for reviews, see [4,21]), while
the former group of selenoprotein genes have generally less well-characterized function, especially
regarding how they may affect colorectal function and CRC development. Overall, any functional
consequences from genetic variations in these genes, together with Se status, may affect several oxidative
stress, inflammatory, and signal translation pathways implicated in colorectal carcinogenesis [13,39].
Notably several of these genes are ER-resident selenoproteins (SELENOF, SELENOM, SELENON,
SELENOT), thought to be involved in ER-stress response and calcium flux, comprising a potentially
important mechanism of selenoprotein-related cancer prevention or promotion [40].
None of the 3 GPX1 SNPs (rs17080528, rs3448, rs9818758) or rs2074451 in GPX4 associated with
CRC risk are in high LD (i.e., r2 ≥ 0.8) to the functionalGPX1Pro/Leu rs1050450 andGPX4 rs713041 SNPs
(for which the Illumina assays failed) previously implicated in prostate, breast, lung (rs1050450), and
CRC risk (rs713041) [4]. However, from these pathway 1 genes, only a TXNRD1 selenoprotein variant
(rs11111979), one of the three thioredoxin reductases which function in redox control [8], remained
borderline significant for an increased CRC risk when applying gene-wide variance considerations
by the PACT method. Interestingly, this SNP inducing a change in the 5′untranslated region of
TXNRD1, among others in TXNRD1, was previously observed to be associated with age-related
physical performance [35], and age is a primary risk factor for CRC development [41]. In the wider
metabolic pathway, following adjustment for multiple testing, genotypes for SNPs in Wnt, TGF-beta
signaling, and apoptosis pathway genes (C-MYC, FRZB, SMAD3, SMAD7, BMP2, and BAX) were also
significantly associated with CRC risk.
Positive associations of selenoprotein gene variants with CRC risk have been more commonly
reported in areas with suboptimal Se availability such as European populations, than regions with
generally adequate Se intake (e.g., North America). However, tagSNPs in several selenoprotein genes
(GPX3, TXNRD3, SELENON, SELENOF, and SELENOX) were also associated with colon or rectal
cancer risk and/or survival outcomes in two separate studies of several large case-control USA cohorts
drawn from populations with generally adequate dietary Se intakes [22,23]. Associations of multiple
SNPs in the same selenoprotein gene with CRC risk were observed in this study for GPX1, SELENON,
TXNRD1, and TXNRD2 (3, 4, 3, and 3 SNPs, respectively), broadly comparable to previous reports [4].
As reported by Slattery et al. in 2012 many of the same selenoprotein genes were separately associated
with colon and rectal cancer risk in sub-site analyses although risks often differed by SNP [22]. From
the 4 SELENON variants that were associated with CRC risk (rs11247735, rs2072749, rs4659382, and
rs11247710), the first 3 were previously associated with rectal cancer risk in this North American
cohort [22]. In our sub-site analyses, rs11247735, rs2072749, and rs11247710 were associated with rectal
cancer risk only, and rs4659382 with both colon and rectal cancer. We also found further modifications
of gene only and gene-Se risk for CRC by sex, as indicated by our previous studies of selenoprotein
genetic variation in a Czech population [19] and Se status in the EPIC study [5]. This reflects the
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importance of interactions between Se intake, Se status and genotype, sex and CRC sub-type risks
(reviewed in [4]).
Prior to this study there were few data available on the interaction of selenoprotein genotype and
Se status regarding CRC risk, apart from a study in a Se replete population of North American women
which reported that the null results for serum Se did not differ by selenoenzyme (GPX1-4 and SELENOP)
genetic variants [17]. The effect of Se pathway SNPs on the efficacy of Se utilization may be particularly
relevant to CRC risk in populations with sub-optimal Se status, such as this study within EPIC [5]. We
observed that numerous genetic variations were associated with Se status levels (as assessed by serum
Se and SELENOP concentration), although these were not significant after adjustment for multiple
tests. However, in the PIGE analysis overall gene and pathway genetic variation interacted with
biomarkers of Se status to alter CRC risk. As expected, there were several variations in pathway 1
nominally associated with Se status levels. These included selenoprotein genes SELENON, SELENOP,
SELENOS, and TXNRD1 that are regulated by Se availability and whose genetic variations have been
previously shown to affect blood and tissue Se levels [6,21,42,43]. Transgenic mouse studies underlined
the critical function of SELENOP for Se organification and transport [11]. Thus, SNP interactions with
SELENOP levels may be particularly important regarding CRC risk as serum SELENOP is a functional
marker of Se status and is more associated with CRC risk than Se in this cohort [5]. Notably, all 4 of
the variants associated with both SELENOP status and CRC risk in the SNP only analysis were from
2 selenoprotein genes; rs4659382, rs11247710, and rs2072749 in SELENON and the PACT borderline
significant rs11111979 variant in TXNRD1. Selenoproteins SELENOP, SELENON, and TXNRD1 are
antioxidant enzymes and their genetic variations plus regulation by SELENOP levels may be important
factors in relation to colorectal carcinogenesis. We observed an association of SELENOP levels with
rs6413428 in SELENOP, which in a SNP-only analysis was previously observed to be associated with
CRC risk in the USA [44], an area of generally high Se status, but not in our study. Another SELENOP
variant, rs3877899, was also associated with SELENOP status, while the GG genotype for this SNP
previously showed the highest significant correlation of all selenoprotein genotypes tested between
serum Se and activity of the vital antioxidant enzyme thioredoxin reductase [45]. This latter study
also showed a correlation between serum Se and increased DNA damage with SELENOS-rs4965373
under peroxide challenge. We selected rs12910524 in SELENOS as a proxy tagSNP for this variant (as
rs4965373 failed Illumina assay development) and found that it was significantly associated with Se
levels. The lipoprotein megalin receptor (LRP2) protein appears to mediate SELENOP uptake to various
tissues and affect plasma Se status levels [46,47]. Here, the LRP2 SNPs rs12614394, rs2229266, rs2389557,
rs700552, and rs9789747 were associated with CRC risk alone while the rs3755166 promoter SNP was
associated with Se levels. Previously, rs3755166 has been associated with Alzheimer’s disease with
the rare allele showing decreased transcriptional activity [48]. Intriguingly, this indicates a potential
mechanism for the suggested link of sub-optimal Se status with neurodegenerative disease [49].
Supporting the data presented here, GPX1 and GPX4 selenoprotein gene loci have been implicated
in GWAS of inflammatory bowel disease (IBD), which is a risk factor for CRC development [50,51].
Additionally, the rs7901303 variant from the selenophosphate synthetase 1 (SEPHS1) gene, which plays
a major role in selenoprotein synthesis, was associated in this study with CRC risk (before multiple
testing corrections). rs7901303 was previously associated with risk of Crohn’s disease in interaction
with serum Se levels in a sub-optimal Se population of New Zealand [52]. The genetic associations
identified in these studies suggest therefore a key role of the corresponding proteins in colorectal
function and/or the carcinogenic process.
Genomic studies and animal models have shown Se intake to not only affect expression of
selenoprotein genes but also pathways key to colorectal carcinogenesis such as the antioxidant
response, immune and inflammatory pathways (including NFkB and Nrf2 signaling) and the Wnt
signaling pathway [4,13,53]. Furthermore, expression of constituents of these metabolic pathways
has been shown to be affected by Se level in human rectal biopsies [54]. Therefore, in addition to a
focus on Se metabolism and selenoprotein genes, the present analysis also encompassed a substantial
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examination of genetic variations in these selenium-relevant pathways. Associations of multiple SNPs
in the same gene (several of which are novel) with CRC risk were observed in genes from pathways 2–8,
e.g., BAX, GPX5, FOXO3, IL12B, TLR4, MSH2, MSH3, TGFB1, as well as IL10 with rectal cancer risk.
Polymorphisms in several of these genes have previously been associated with CRC risk [55–62]. After
BH multiple testing corrections, SNPs in cell-signaling pathways retained significance (FRZB, SMAD3,
and SMAD7). The variants in both SMAD genes were previously linked to CRC by GWAS, suggesting
a role of these variants in CRC development [38]. The association of rs17265803 in FRZB appears to
be novel and it is not in LD with the functional FRZB genetic variant Arg324Gly (rs7775) previously
reported to be associated with an increased CRC risk [63], although this was not replicated in a nested
case-control study [64]. Additional genetic variants retaining significance by PACT were rs6983267 in
C-MYC previously identified in a meta-GWAS [65], rs235770 in BMP2 previously associated with colon
cancer risk [37], and a novel association of rs4645887 in BAX.
In the pathway analysis, all the Se pathway genes were grouped into a primary best-known
functional pathway and were analyzed for the association of whole gene and whole pathway genetic
variation with CRC risk, and in interaction with Se status. Neither gene only variation or interactions
with Se status in the core pathway 1 selenoprotein and biosynthesis pathway were associated with CRC
risk by pathway, although gene only variation for GPX1, SELENOM, SELENON, and SEPHS1 plus gene
x Se status interactions for SELENON (with SELENOP) and PSTK (with Se) were associated with CRC
risk. In the gene x Se analysis, only pathway 2 (antioxidant/redox) was significant for an association
with CRC risk for both Se and SELENOP. Alternatively, it also remains possible that the genetic ‘noise’
from any irrelevant selenoproteins masked the overall risk associations for pathway 1 (based on the
rationale that most genes in pathways like oxidative stress are important in cancer prevention but that
some of the selenoproteins may be irrelevant to colorectal carcinogenesis, as they are included solely
because they share selenocysteine motifs). This is partly supported by the strongest association (by
PIGE) in pathway 1 for gene variance in GPX1, which has been previously implicated in risk of various
cancers [4]. However, these pathway divisions cannot reflect, for example, the biological overlaps with
the antioxidant selenoprotein genes in pathway 1 and their non-Se containing counterparts in pathway
2. Several aspects of our data suggest a potentially under-appreciated focus on variation in apoptosis
genes (pathway 4) and CRC risk that may also be modified by Se status. These comprise the association
of several SNPs in both the FOXO3 and BAX genes (including the PACT significant rs4645887 variant in
BAX) with CRC risk, significance of FOXO3 for overall gene variation, and several significant findings
of SNP x Se and gene x Se status interactions for genes in this pathway (e.g., SMAC, CASP8, MAPK8,
and MAPK9). Overall, our analyses suggest that genetic variation in TGF beta signaling (pathway
7), which includes members such as BMP2, BMPR2, SMAD3, and SMAD7 implicated in CRC risk by
previous large case-control and GWAS reports [36–38], is sufficient to alter CRC risk, independent of
Se status interaction, while SNP risk associations attributed to the antioxidant and apoptosis pathways
may be significantly modified by Se status interactions.
Strengths and weaknesses of our study design for the Se status analyses have been discussed
earlier [5]. The hypothesis-driven approach and appreciable sample size within a large, prospective
study allowed an extensive examination of Se pathway genetic variation (including gene pathway
analyses) and the interaction with robust markers of Se status regarding CRC risk. Despite the large
sample size, gene pathway, gene–Se interaction analysis and some stratified analyses had limited
power, particularly analyses by sex and anatomical sub-sites. The pathway designations were assigned
based on known function from the literature, and there will be interactions between these pathways
that we were not able to model. Finally, as most of the reported associations involve tagSNPs of
no known functionality (or the actual contributing functional variant(s) they tag) additional genetic
mapping and lab-based studies will be needed to explore these aspects.
Nutrients 2019, 11, 935 15 of 19
5. Conclusions
In summary, the present study indicates that genetic variation in selenoprotein genes and genes
in antioxidant/redox, Wnt, apoptotic, and TGF-beta signaling pathways may modify risk of CRC
development. Furthermore, for genes in antioxidant/redox and apoptotic pathways the influence
of SNPs on the disease risk is also dependent on interaction with Se status. Overall, these results
taken together with our previous study [5] suggest that risk of CRC may be modified by genotype,
Se status, sex, and gene variation interactions within biological pathways. Thus, will individuals
harboring these genotypes benefit from increased Se intake, including consideration of ‘Se adequate’
environments, such as the US, where Se intervention trials have not shown a significant benefit in the
general population [66]? Before such a recommendation can be defined, further examination of these
findings in other populations and investigation of Se metabolism is needed to clarify the relevance of
the Se pathway and signaling genotypes for CRC etio-pathogenesis, especially for individuals with
suboptimal Se status.
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